PLEASANTON, Calif.--(BUSINESS WIRE)--Veeva Systems (NYSE:VEEV) will host the 2018 Veeva R&D Summit from September 16-18 in Philadelphia. The event will bring together more than 1,300 life sciences professionals and experts showcasing the latest advancements for speeding product development in the industry.
The conference opens with Nick Leschly, chief bluebird at bluebird bio, discussing the potential of breakthrough innovations in treating genetic and rare diseases. Mr. Leschly will sit down with Matt Wallach, president and co-founder of Veeva, in a fireside chat on “Bringing Gene Therapy-Powered Hope to Reality.”
More than 100 leading pharmaceutical, biotech, and medical device professionals will share in-depth best practices for streamlining product development processes in clinical, regulatory, and quality. This year’s event features keynotes on optimizing trial performance, reinventing clinical data management, modernizing quality management, and regulatory transformation:
- Janssen Pharmaceuticals, Pharmaceutical Product Development LLC (PPD), and IACT Health identify opportunities to improve clinical information exchange for better trial collaboration and execution across sponsors, CROs, and sites.
- Cara Therapeutics explains how they improved clinical data management with a modern EDC solution to speed study database build and design.
- Bristol-Myers Squibb share their vision to modernize quality management globally and transform the change management process with a strategic, enterprise-wide initiative.
- Eli Lilly and Company discuss their innovative approach to RIM transformation and implementing an end-to-end process for post-approval changes on a single RIM platform.
Veeva founder and CEO, Peter Gassner, will deliver a keynote on how Veeva Vault is enabling the industry to transform product development processes in clinical, regulatory, quality, and soon safety. He will also unveil Veeva’s vision to help sponsors, CROs, and sites seamlessly collaborate during clinical trials. Jen Goldsmith, senior vice president of Veeva Vault, and Avril England, general manager of Veeva Vault, will showcase how Veeva Development Cloud manages global end-to-end processes such as variation management and change control across research and development.
More than 60 sessions and workshops will feature speakers from AbbVie, Agios Pharmaceuticals, Alkermes PLC, Allakos, Atlantic Research Group, BioEnterprise, Clintec, Gilead Sciences, Inc., GlaxoSmithKline, ICON plc, Incyte Corporation, Integra LifeSciences, Intersect ENT, Ionis Pharmaceuticals, Inc., Melinta Therapeutics Inc., Ora, Inc., Radius Health, Regeneron Pharmaceuticals Inc., Replimune Group Inc., Seattle Genetics, Inc., Syneos Health, Sysmex Corporation, TESARO, Inc., Ultragenyx Pharmaceutical Inc., and Upsher-Smith Laboratories LLC, among others.
2018 Veeva R&D Summit is sponsored by Accenture, AG Mednet, Amazon Web Services, C3i Solutions, CGI, Cognizant, Comprehend Systems, Inc., Deloitte, EY, FME, Ideagen Plc, LPW Training Services, Mavens, NNIT, Qlik, SDL, Tata Consultancy Services, Trifecta, UL PURE Learning, and Valiance Partners.
In other news today, Veeva announced the availability of Veeva Vault Submissions Publishing, as well as continued momentum with customers adopting Veeva Vault CTMS. Read the Vault Submissions Publishing news and Vault CTMS news to learn more.
Veeva R&D Summit is a complimentary event for Veeva customers and invited guests. Learn more, register, and view the full agenda at veeva.com/R&DSummit.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 650 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.